Neurotrope (NASDAQ: NTRP) is one of 577 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Neurotrope to similar companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, risk, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings and target prices for Neurotrope and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurotrope 0 0 2 0 3.00
Neurotrope Competitors 5128 14348 29517 1087 2.53

Neurotrope presently has a consensus target price of $15.00, indicating a potential upside of 158.62%. As a group, “Pharmaceutical preparations” companies have a potential downside of 99.98%. Given Neurotrope’s stronger consensus rating and higher probable upside, equities analysts plainly believe Neurotrope is more favorable than its rivals.

Institutional & Insider Ownership

14.0% of Neurotrope shares are owned by institutional investors. Comparatively, 45.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 9.7% of Neurotrope shares are owned by insiders. Comparatively, 15.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Neurotrope and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neurotrope N/A -77.18% -70.43%
Neurotrope Competitors -1,534.50% -905.78% -29.31%

Risk & Volatility

Neurotrope has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Neurotrope’s rivals have a beta of 1.20, indicating that their average share price is 20% more volatile than the S&P 500.

Earnings and Valuation

This table compares Neurotrope and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Neurotrope N/A -$11.02 million -4.23
Neurotrope Competitors $2.14 billion $227.34 million -119,068.19

Neurotrope’s rivals have higher revenue and earnings than Neurotrope. Neurotrope is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


Neurotrope beats its rivals on 7 of the 13 factors compared.

Neurotrope Company Profile

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with's FREE daily email newsletter.